A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab and Milk Oral Immunotherapy for the Treatment of Patients with Cow's Milk Allergy
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Milk hypersensitivity
- Focus Therapeutic Use
Most Recent Events
- 10 Mar 2025 Status changed from active, no longer recruiting to discontinued.
- 02 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2023 Planned End Date changed from 1 May 2024 to 1 Nov 2026.